Michael Yang, MD
Neurology · la Crosse, WINPI 1265826762
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $116,966 of the $152,792 with a category attached, or 76.6%. 14 manufacturers reported payments, led by Lundbeck LLC at 53.5% of the total. 2025 is the largest year on record at $68,275, more than ten times the $105 reported in 2019. Among neurology clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $385.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$82K
- Pfizer$24K
- Axsome Therapeutics, Inc.$18K
- AbbVie$14K
- Biohaven Pharmaceuticals, Inc.$12K
- Globus Medical$481
- plus $800 from 8 others
Across 9 payments — averaging $3546.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz Pharmaceuticals, LLC$27K
- Pfizer$4K
What the payments were for
- Consulting fees$16,14411%
- Speaking & faculty fees$116,96677%
- Travel & lodging$12,5998%
- Food & beverage$7,0845%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 217 | $81,702 |
| Pfizer | 31 | $24,470 |
| Axsome Therapeutics, Inc. | 36 | $18,445 |
| AbbVie | 70 | $14,431 |
| Biohaven Pharmaceuticals, Inc. | 23 | $12,463 |
| Globus Medical | 4 | $481 |
| Impel Pharmaceuticals Inc. | 3 | $205 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $193 |
| Tonix Medicines, Inc. | 1 | $181 |
| Amgen | 1 | $79 |
| Abbott | 2 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Lilly USA, LLC | 1 | $28 |
| AstraZeneca | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$77,284
- NURTEC ODT$24,968
- Symbravo$17,770
- ZAVZPRET$10,953
- QULIPTA$9,901
- UBRELVY$8,438
- RELINE$188
- Pulse$188
- ZEMBRACE SYMTOUCH$181
- TOSYMRA$181
How this compares
$152,792 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 117 | $215,137 |
| Emgality PenGalcanezumab-Gnlm | 198 | $141,264 |
| UbrelvyUbrogepant | 86 | $120,891 |
| Aimovig AutoinjectorErenumab-Aooe | 108 | $78,081 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 67 | $53,873 |
| QuliptaAtogepant | 37 | $45,243 |
| ReyvowLasmiditan Succinate | 30 | $22,497 |
| Almotriptan Malate | 13 | $5,419 |
| Trokendi XrTopiramate | 11 | $5,199 |
| Lacosamide | 12 | $4,600 |
| Sumatriptan Succinate | 93 | $4,540 |
| RizatriptanRizatriptan Benzoate | 118 | $2,253 |
| Carbamazepine | 15 | $1,469 |
| Oxcarbazepine | 20 | $1,256 |
| Zolmitriptan OdtZolmitriptan | 12 | $1,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $24,470 | $215,137117 claims |
| AbbVieUbrelvy, Qulipta | $14,431 | $166,134123 claims |
| Lilly USA, LLCReyvow | $28 | $22,49730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Wisconsin.
Other neurology in la Crosse
- Paul Spanella Crosse$23K
- Michael Doerrlerla Crosse$9K
- Smathorn Thakolwiboonla Crosse$4K
- Bhupendra KhatriMilwaukee$2.5M
- Ahmed ObeidatMilwaukee$1.9M
- Staley BrodMilwaukee$1M
- Daniel LongNeenah$899K
- Traci PurathBurlington$524K
- Ashley HoldridgeWhitefish Bay$368K
- Michael SnyderMadison$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.